These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://emilievwbs376617.amoblog.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-60921775